News
Resources
Blog
Sites
PhRMA releases 2021 industry profile
By Gabby Migliara | September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story...
Read More
Addressing data challenges to improve health equity
By Emily Donaldson | September 17, 2021
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to...
Read More
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
By Stephen J. Ubl | September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...
Read More
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
By Joseph Havey | September 8, 2021
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. Already, we’ve...
Read More
Patients and innovators lose if the government pursues ‘march-in’
By Megan Van Etten | September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...
Read More
The impact of monoclonal antibodies and COVID-19 recovery
By Andrew Powaleny | September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...
Read More
Recent polling misrepresents public support for Medicare “negotiation”
By Tom Wilbur | August 31, 2021
Proponents of government price setting often misrepresent voters’ opinions on support for allowing the federal government to “negotiate” drug prices. This includes recent polling from advocacy...
Read More
Recognizing National Immunization Awareness Month
By Richard Moscicki, M.D. | August 31, 2021
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...
Read More
What they’re saying: Patient advocates want to protect Medicare from government interference
By Gabby Migliara | August 24, 2021
For seniors and people with disabilities, Medicare Parts B and D provide important access to lifesaving medicines. Unfortunately, some in Congress are proposing changes to Medicare under the guise...
Read More
Driving further innovation is critical to global vaccine equity
By Megan Van Etten | August 24, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
